S

Southern California Research Center | Coronado, CA

Research site
(Unclaimed)
Location
131 Orange Avenue, Suite 101, Coronado, California, United States of America

Site insights

Top conditions

Top treatments

EDP-305
Ribavirin
TD-6450
ABI-H0731
BMS-650032
Daclatasvir
Golimumab
BMS-790052
Semaglutide
Elafibranor

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 57 total trials

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (ELFIDENCE)

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC).Participants will also have inadequate response or intolerance t...

Enrolling
Primary Biliary Cholangitis (PBC)
Drug: Elafibranor
Other: Matched 80 mg placebo

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Enrolling
NASH
Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This study is researching an investigational drug called ALN-HSD (called "study drug"). This study is focused on participants who are known to have n...

Enrolling
Non-alcoholic Steatohepatitis (NASH)
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Drug: Placebo
Drug: ALN-HSD

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Enrolling
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Enrolling
Colitis, Ulcerative
Drug: Placebo
Biological: Golimumab

This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with...

Active, not recruiting
Hepatocellular Carcinoma
Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib
Drug: Nofazinlimab (CS1003)+Lenvatinib

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
PBC
Primary Biliary Cholangitis
Drug: Volixibat
Drug: Placebo

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
Primary Sclerosing Cholangitis
Drug: Volixibat
Drug: Placebo

This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical tr...

Active, not recruiting
Decompensated Cirrhosis and Ascites
Other: Standard medical treatment
Drug: Albutein 20% Injectable Solution

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to se...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: Efavaleukin alfa

This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum...

Enrolling
Acute-On-Chronic Liver Failure
Other: Standard Medical Treatment
Biological: SMT + PE-A 5%

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: PTM CILO/FIR
Drug: Cilofexor (CILO)/Firsocostat (FIR)

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderat...

Enrolling
Ulcerative Colitis
Drug: Tilpisertib Fosmecarbil
Drug: Placebo

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Scler...

Active, not recruiting
Pruritus
Drug: EP547
Drug: Placebo

A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subj...

Enrolling
NON-ALCOHOLIC STEATOHEPATITIS
Drug: Sitagliptin
Drug: DA-1241 Placebo

This study is a Phase 2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple asce...

Active, not recruiting
Primary Biliary Cholangitis
Drug: CNP-104
Drug: Placebo

Trial sponsors

Gilead Sciences logo
A
Bristol-Myers Squibb (BMS) logo
Enanta Pharmaceuticals logo
Grifols logo
Mirum Pharmaceuticals logo
Boehringer Ingelheim logo
J
Pfizer logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems